Patent · US Active

(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors

US9487512B2 · kind B2 · utility

7Cited by

21References

60Claims

0Family size

Assignee

Oryzon Genomics S.A. · ES

Inventors

Alberto Ortega Muñoz · Barcelona, ES
Matthew Colin Thor Fyfe · Chipping Norton, GB
Marc Martinell Pedemonte · Barcelona, ES
Maria de los Àngeles Estiarte Martinez · San Francisco, US
Nuria Valls Vidal · Barcelona, ES
Guido Kurz · Barcelona, ES
Julio Cesar Castro Palomino Laria · Premià de Mar, ES

Key dates

Filing date	Oct 22, 2012
Grant date	Nov 8, 2016
Priority date	—
Expiry date	Oct 22, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D451/04
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.